GHIC Announces $10M Investment in Aerska to Advance Systemic Delivery of RNA Medicines to the Brain

NEW YORK, NY – Global Health Investment Corporation (GHIC) today announced a $10 million investment in Aerska, a biotechnology company using brain shuttle technology to develop RNA medicines for CNS diseases. The investment forms part of Aerska’s Series A financing, which was originally announced as a $39 million financing led by EQT Dementia Fund and age1, with participation from Iaso Ventures and existing investors. The funding will be used to advance its brain shuttle technology to improve delivery of RNA interference (RNAi) therapeutics across the blood-brain barrier for treating neurological diseases.

This brings total funds raised to $70 million to-date, months after its seed funding announcement in October 2025. Proceeds will support continued development of Aerska’s antibody-oligo conjugate (AOC) platform as it progresses toward the clinic targeting neurological diseases through systemically delivered RNAi therapeutics.

Aerska’s AOC platform is pioneering systemically delivered RNA medicines capable of reaching the brain to treat neurological diseases at their source. The platform uses proprietary “brain shuttle” technology to overcome the blood-brain barrier, a fundamental challenge that has historically limited RNA therapeutics in CNS diseases. This delivery approach is designed to enable intravenous or subcutaneous administration, achieving uniform and deep brain distribution with durable target gene knockdown, unlocking new therapeutic possibilities for neurological diseases.

As part of GHIC’s investment, Aerska will advance platform development work focused on improving the selectivity of their payloads to the brain and looking at emerging approaches to target multiple pathways simultaneously. The work will provide valuable insight into the platform’s potential in developing novel treatments for severe neurotropic viral infections, an area where new therapeutic approaches are needed and where adaptable platform technologies may play an important role in future health security preparedness.

About Aerska

Aerska is a biotechnology company pioneering RNA medicines to treat, delay and prevent diseases of the brain. The company is leveraging advances in ‘brain shuttles’ to enable targeted delivery of next-generation RNAi therapeutics to the CNS. By silencing the genes that cause harm, Aerska aims to preserve the minds, protect the memories, and enable our loved ones to live longer, healthier lives. Aerska is headquartered in Dublin, Ireland, with research operations in London, UK. For more info, visit www.aerska.com.

About Global Health Investment Corporation (GHIC)

A pioneer of investing in global health, GHIC has been supporting high-impact biomedical innovations for over a decade. GHIC's Global Health Investment Fund (GHIF) financed the development of products to combat public health challenges that disproportionately affect people living in low- and middle-income countries. In 2021, GHIC entered a 10-year venture investment partnership with the Biomedical Advanced Research and Development Authority (BARDA) focused on global health security.